Genmab A+s

Medarex Inc.

Marcus A Van Dijk

Arnout F Gerritsen

Jan G J Van De Winkel

Ole Baadsgaard

Janine Schuurman

Jørgen Petersen

Edward L Halk

Jan Van De Winkel

Debra Hudson

Jorgen Petersen

Jørgen Peterson

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15)

Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)

Human antibodies specific for interleukin 15 (IL-15)

Methods of treating using anti-IL-15 antibodies

Human monoclonal antibodies which bind specifically to Fc alpha receptor (CD89), including monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The binding agents, e.g., antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.

Human monoclonal antibodies to FC alpha receptor (CD89)

Growing community of inventors

Bilthoven, Netherlands

Marcus A Van Dijk